Safety Evaluation Study for Patients With Polycythemia Vera

Phase I, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of A Single Intravenous PPMX-T003 in Polycythemia Vera

This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003 in Polycythemia Vera

Inclusion Criteria:

• Confirmed diagnosis of PV according to either the 2008 or 2016 WHO classification criteria
• PV patients being only treated with phlebotomy and the interval is 4-9 weeks

Exclusion Criteria:

• Patients administrated drugs for PV treatment such as hydroxyurea or ruxolitinib (aspirin is excluded)